Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii
Kamal El Bissati, … , Craig W. Roberts, Rima McLeod
Kamal El Bissati, … , Craig W. Roberts, Rima McLeod
Published September 22, 2016
Citation Information: JCI Insight. 2016;1(15):e85955. https://doi.org/10.1172/jci.insight.85955.
View: Text | PDF
Research Article Vaccines

Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii

  • Text
  • PDF
Abstract

We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand emulsion adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion [GLA-SE]) for their ability to protect against Toxoplasma gondii in HLA transgenic mice. Our constructs each included 5 of our best down-selected CD8+ T cell–eliciting epitopes, a universal CD4+ helper T lymphocyte epitope (PADRE), and a secretory signal, all arranged for optimal MHC-I presentation. Their capacity to elicit immune and protective responses was studied using immunization of HLA-A*11:01 transgenic mice. These multi-epitope vaccines increased memory CD8+ T cells that produced IFN-γ and protected mice against parasite burden when challenged with T. gondii. Endocytosis of emulsion-trapped protein and cross presentation of the antigens must account for the immunogenicity of our adjuvanted protein. Thus, our work creates an adjuvanted platform assembly of peptides resulting in cross presentation of CD8+ T cell–eliciting epitopes in a vaccine that prevents toxoplasmosis.

Authors

Kamal El Bissati, Aziz A. Chentoufi, Paulette A. Krishack, Ying Zhou, Stuart Woods, Jitender P. Dubey, Lo Vang, Joseph Lykins, Kate E. Broderick, Ernest Mui, Yasuhiro Suzuki, Qila Sa, Stephanie Bi, Nestor Cardona, Shiv K. Verma, Laura Fraczek, Catherine A. Reardon, John Sidney, Jeff Alexander, Alessandro Sette, Tom Vedvick, Chris Fox, Jeffrey A. Guderian, Steven Reed, Craig W. Roberts, Rima McLeod

×

Figure 5

Multivalent polypeptide LO and AZ protective efficacy in vivo with HLA-A*11:01 transgenic mice survival curve after challenge with Type II parasites.

Options: View larger image (or click on image) Download as PowerPoint
Multivalent polypeptide LO and AZ protective efficacy in vivo with HLA-A...
Two weeks after last immunization, the transgenic mice immunized with pooled LO and AZ proteins (prot) in combination with either adjuvant GLA-SE or ALUM adjuvant or injected with PBS were infected with 2,000 Me49 (Fluc) parasites. The survival rates of the 2 groups were recorded. This figure shows data from mice in both of 2 replicate experiments combined (n = 5 control and 5 immunized mice). Kaplan-Meier curves were generated and survival compared across groups using the log-rank test, P < 0.05. Differences between protLO+AZ + GLA-SE and all other groups were significant (P < 0.05) and differences between protLO+AZ + GLA-SE and protLO+AZ + ALUM also were compared for survival using log-rank test and Kaplan-Meier analysis.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts